Company profile: Cergentis
1.1 - Company Overview
Company description
- Provider of services and kits based on proprietary Targeted Locus Amplification (TLA) technology, enabling cost-effective complete sequencing of relevant genes and genomic loci and providing genetic characterization and quality control (QC) to support the development of advanced, safe and effective therapies.
Products and services
- Genetic Characterization Services: Research-grade TLA-based analyses that characterize genetic material through complete sequencing of genes and genomic loci to support therapy development
- Quality Control (QC) Services: Analytical-grade TLA-based testing ensuring quality and safety of genetic materials through rigorous analysis of genes and genomic loci
- Targeted Locus Amplification (TLA) technology: Proprietary platform enabling complete sequencing of genes and genomic loci for genetic characterization and quality control.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cergentis
GenEdit
HQ: United States
Website
- Description: Provider of a proprietary non-viral, non-lipid polymer nanoparticle platform (NanoGalaxy) for safe, efficient delivery of genetic medicine payloads—including nucleic acids, therapeutic proteins, and CRISPR/Cas9—to specific tissues. Offers tissue selectivity, payload flexibility, ability to redose without immune response, and scalable manufacturing with batch-to-batch purity and long-term stability that reduces cold-chain logistics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GenEdit company profile →
Rome Therapeutics
HQ: United States
Website
- Description: Provider of novel therapies for cancer and autoimmune diseases harnessing the repeatome, including development of LINE-1 reverse transcriptase inhibitors for autoimmune diseases, supported by a data science platform that identifies active elements in the dark genome and assesses their roles in disease to guide drug development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rome Therapeutics company profile →
Phthisis Diagnostics
HQ: United States
Website
- Description: Provider of molecular diagnostics products for various infectious diseases, leveraging molecular technology to deliver superior quality, ease of use, and cost savings for laboratories.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Phthisis Diagnostics company profile →
Lentigen Technology
HQ: United States
Website
- Description: Provider of gene delivery technologies and CDMO services for cell and gene therapy products, offering lentiviral vector technology for therapeutic, vaccine, and research applications; lentiviral vector design, evaluation, and scalable manufacturing; process development and clinical manufacturing; assay development via automated flow cytometry; and regulatory support from pre-IND to approval.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lentigen Technology company profile →
Senti Bio
HQ: United States
Website
- Description: Provider of synthetic biology-driven cell and gene therapies for cancer, featuring a Gene Circuit platform to program therapies, off-the-shelf CAR-NK cell therapies, and investigational candidates SENTI-202 (logic-gated targeting of CD33/FLT3 for hematologic malignancies incl. AML) and SENTI-301A (for GPC3+ tumors with crIL-15 Gene Circuit), with manufacturing via GeneFab.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Senti Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cergentis
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cergentis
2.2 - Growth funds investing in similar companies to Cergentis
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cergentis
4.2 - Public trading comparable groups for Cergentis
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →